FY2030 EPS Estimates for Rezolute Reduced by HC Wainwright

Rezolute, Inc. (NASDAQ:RZLT) – Analysts at HC Wainwright lowered their FY2030 EPS estimates for Rezolute in a note issued to investors on Friday, December 12th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $0.37 for the year, down from their prior estimate of $0.49. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Rezolute’s current full-year earnings is ($0.93) per share.

Rezolute (NASDAQ:RZLT) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.09.

Several other equities research analysts have also commented on RZLT. JMP Securities set a $17.00 price target on shares of Rezolute in a research note on Wednesday, October 29th. Citigroup cut Rezolute from an “outperform” rating to a “market perform” rating in a research report on Thursday. Wall Street Zen lowered Rezolute from a “hold” rating to a “sell” rating in a research report on Saturday. Citizens Jmp lowered Rezolute from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 11th. Finally, Maxim Group set a $4.00 price objective on shares of Rezolute in a report on Friday. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $9.78.

Rezolute Trading Down 9.4%

Shares of NASDAQ RZLT opened at $1.63 on Monday. The company has a market cap of $151.15 million, a price-to-earnings ratio of -1.75 and a beta of 0.21. The stock’s 50 day simple moving average is $9.00 and its 200 day simple moving average is $7.17. Rezolute has a 12-month low of $1.07 and a 12-month high of $11.46.

Insider Activity at Rezolute

In related news, CFO Daron Evans bought 40,000 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was bought at an average price of $1.77 per share, with a total value of $70,800.00. Following the purchase, the chief financial officer directly owned 415,900 shares of the company’s stock, valued at approximately $736,143. This represents a 10.64% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Nevan C. Elam acquired 32,000 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average price of $1.59 per share, for a total transaction of $50,880.00. Following the acquisition, the chief executive officer directly owned 641,119 shares of the company’s stock, valued at $1,019,379.21. The trade was a 5.25% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have purchased 89,100 shares of company stock valued at $150,232. 14.78% of the stock is currently owned by corporate insiders.

Institutional Trading of Rezolute

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets acquired a new stake in shares of Rezolute during the 2nd quarter worth approximately $25,000. Ameritas Investment Partners Inc. bought a new stake in Rezolute during the second quarter worth about $30,000. Legal & General Group Plc acquired a new stake in Rezolute during the 2nd quarter valued at $32,000. Raymond James Financial Inc. bought a new position in shares of Rezolute in the second quarter valued at about $46,000. Finally, Paloma Partners Management Co acquired a new stake in Rezolute in the 1st quarter valued at about $48,000. Institutional investors own 82.97% of the company’s stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.